Literature DB >> 6778926

Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies.

R B Fick, G P Naegel, H Y Reynolds.   

Abstract

Potent, mono-specific anti-Pseudomonas immunoglobulins were isolated from serum and lung lavage fluid from patients with cystic fibrosis using immunotype specific Pseudomonas aeruginosa lipopolysaccharide (LPS) substituted immunoadsorbent gel. Iodinated monovalent Pseudomonas LPS somatic antigens, Fisher immunotypes, were used as ligands for two different insoluble gel matrices. LPS iodination, using the water insoluble chloroglycoluril reagent, permitted quantitation of the percent LPS bound as a ligand. The coupling efficiencies of epoxy-activated and cyanogen bromide-activated Sepharose matrices for various Pseudomonas immunotype specific LPS preparations were compared. Although each of the 7 LPS somatic antigens produced an equivalent amount of coupling, higher percentages of coupling were found using the cyanogen bromide-activated gel when compared to the epoxy-activated gel. IgG fractions prepared from cystic fibrosis sera and lung lavage fluid were passed through the LPS affinity gels, and Pseudomonas LPS immunotype specific antibodies were eluted. The presence of specific antibody activity against individual Pseudomonas immunotypes was determined with a passive micro-hemagglutination assay. Bronchial lavage fluid seemed to be as effective as serum as a source of Pseudomonas specific antibody. Use of such a LPS substituted gel permits direct recovery of Pseudomonas monospecific antibodies suitable for physical-chemical analyses and for biologic functional assays.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6778926     DOI: 10.1016/0022-1759(80)90335-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Cleavage of immunoglobulin G (IgG) and IgA around the hinge region by proteases from Serratia marcescens.

Authors:  A Molla; T Kagimoto; H Maeda
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

2.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

3.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains.

Authors:  R E Hancock; L M Mutharia; L Chan; R P Darveau; D P Speert; G B Pier
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

5.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay.

Authors:  R B Fick; G P Naegel; R A Matthay; H Y Reynolds
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

6.  Passive protection of mice with antiserum to neuraminidase from Pasteurella multocida serotype A:3.

Authors:  F I Ifeanyi; W E Bailie
Journal:  Vet Res Commun       Date:  1992       Impact factor: 2.459

7.  Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes.

Authors:  A B Petrov; B F Semenov; Y P Vartanyan; M M Zakirov; V P Torchilin; V S Trubetskoy; N V Koshkina; V L L'Vov; I K Verner; I V Lopyrev
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

8.  Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains.

Authors:  N L Schiller
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.